Original GlobalRPh source
- Product / population
- Preserved GlobalRPh source, not a freshly verified product label
- Renal measure
- Use the method specified in the original source
Historical source: not automatically current. Review current official labeling and separately attributed additions before use.
GlobalRPh general renal statement
Renal Insufficiency: The disposition of mirtazapine was studied in patients with varying degrees of renal function. Elimination of mirtazapine is correlated with creatinine clearance.
Total body clearance of mirtazapine was reduced approximately 30% in patients with moderate (Clcr =11 to 39 mL/min/1.73 m2) and approximately 50% in patients with severe (Clcr <=10 mL/min/1.73 m2) renal impairment when compared to normal subjects. Caution is indicated in administering mirtazapine to patients with compromised renal function.
Dosing: Elderly and Patients with Renal or Hepatic Impairment: The clearance of mirtazapine is reduced in elderly patients and in patients with moderate to severe renal or hepatic impairment. Consequently, the prescriber should be aware that plasma mirtazapine levels may be increased in these patient groups, compared to levels observed in younger adults without renal or hepatic impairment.
Source: https://globalrph.com/renal/medications-with-general-renal-dosing-statements/